Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ocugen ( (OCGN) ) just unveiled an announcement.
On August 29, 2025, Ocugen, Inc. entered into a subscription agreement with Carisma Therapeutics Inc. as part of a merger plan involving its subsidiary, OrthoCellix, and Carisma. This agreement is part of a larger $25 million investment plan, with Ocugen committing $5 million to purchase shares of Carisma. This strategic move is expected to strengthen Ocugen’s market position by expanding its investment portfolio and aligning with Carisma’s growth trajectory.
The most recent analyst rating on (OCGN) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Ocugen stock, see the OCGN Stock Forecast page.
Spark’s Take on OCGN Stock
According to Spark, TipRanks’ AI Analyst, OCGN is a Neutral.
Ocugen’s overall stock score is primarily impacted by its precarious financial performance, which poses significant risks. While technical analysis and valuation also reflect challenges, recent earnings call highlights and positive corporate events provide some optimism for future growth and strategic positioning.
To see Spark’s full report on OCGN stock, click here.
More about Ocugen
Ocugen, Inc. is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and a vaccine to fight COVID-19. The company is involved in the development and commercialization of innovative therapies for eye diseases and other medical conditions.
Average Trading Volume: 4,552,602
Technical Sentiment Signal: Hold
Current Market Cap: $321.7M
For a thorough assessment of OCGN stock, go to TipRanks’ Stock Analysis page.